Souce
Indeed, Pfizer admits that clinical trials were short in determining myocarditis risks in children and “misreported” the number of deaths.
It is a report from the FDA where the pharmaceutical company Pfizer has assured that the clinical trials that were carried out on the vaccines were for a very short period of time and therefore "had time" to determine the long-term risk of myocarditis of the patients. children who are vaccinated, logically there has not been an adequate study for children, nor has there been a study for adults, because not even 5 years have passed since this supposed disease.This information appears on page 11 of the report, you can read it yourselves, but I present it to you anyway.
It also states that the sample trial was too small to detect the risk of the disease in children aged 5 to 12 years, despite this the FDA has issued an emergency authorization for children between 5 to 12 years to start to vaccinate.Under what criteria do they evaluate if a child in a "state of emergency" should be given the vaccine that can kill him, someone tell me if this is not a homicide.
To affirm its complicity, the Vaccine contains Tromethamine, which is a drug used to treat metabolic acidosis that often occurs after surgery for cardiac arrest.
Overall Risk-Benefit Conclusions
COVID-19 continues to be a serious and potentially fatal or life-threatening infection forchildren and there is a significant unmet medical need in the 5 to <12 years of agepopulation.
Two primary doses of the 10 µg BNT162b2 vaccine given 3 weeks apart in 5 to <12 years ofage have shown a favorable safety and tolerability profile, robust immune responses againstall variants of concern and high VE against symptomatic COVID-19 in a period where thedelta variant was predominant.
The number of participants in the current clinical development program is too small to detectany potential risks of myocarditis associated with vaccination. Long-term safety ofCOVID-19 vaccine in participants 5 to <12 years of age will be studied in5 post-authorization safety studies, including a 5-year follow-up study to evaluate long termsequelae of post-vaccination myocarditis/pericarditis.
FDA Report